https://lucius-pharmaceuticals.com/drug/erdafitinib-4mg/
Erdafitinib 4mg - Lucius Pharmaceuticals
Erdafitinib 3mg/4mg/5mg are the medication used to treat metastatic urothelial carcinoma, a type of bladder cancer. It belongs to a class of drugs known as...
erdafitinibluciuspharmaceuticals
https://www.jnj.com/innovativemedicine/uk/our-innovation/focus-areas/oncology/smc-approves-balversa-erdafitinib-bladder-cancer-fgfr3
SMC approval of BALVERSA®▼ (erdafitinib) helps pave the way for first licensed bladder cancer...
Oct 27, 2025 - For medical and pharmaceutical trade media
pave the waybladder cancersmcapprovalerdafitinib
https://www.targetedonc.com/shorts/intravesical-erdafitinib-evaluated-in-phase-1-nmibc-trial
Intravesical Erdafitinib Evaluated in Phase 1 NMIBC Trial | Targeted Oncology - Immunotherapy,...
Oct 13, 2026 - Mutated-directed therapy in bladder cancer is explored in a phase 1 trial evaluating erdaftinib delivered intravesically and presented at the 2026 European...
in phaseintravesicalerdafitinibevaluatednmibc